Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Finished Goods (2016 - 2024)

NovaBay Pharmaceuticals (NBY) has disclosed Finished Goods for 12 consecutive years, with $792000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Finished Goods fell 63.47% to $792000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $792000.0, a 63.47% decrease, with the full-year FY2024 number at $792000.0, down 63.47% from a year prior.
  • Finished Goods was $792000.0 for Q4 2024 at NovaBay Pharmaceuticals, up from $732000.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $3.3 million in Q3 2022 to a low of $573000.0 in Q2 2021.
  • A 5-year average of $1.8 million and a median of $1.5 million in 2021 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: skyrocketed 420.77% in 2022, then plummeted 77.16% in 2024.
  • NovaBay Pharmaceuticals' Finished Goods stood at $685000.0 in 2020, then skyrocketed by 291.53% to $2.7 million in 2021, then dropped by 0.71% to $2.7 million in 2022, then decreased by 18.59% to $2.2 million in 2023, then crashed by 63.47% to $792000.0 in 2024.
  • Per Business Quant, the three most recent readings for NBY's Finished Goods are $792000.0 (Q4 2024), $732000.0 (Q1 2024), and $2.2 million (Q4 2023).